Return to QS33 Overview

Rheumatoid arthritis in over 16s [QS33]

Measuring the use of this guidance

Statement: 1

People with suspected persistent synovitis affecting the small joints of the hands or feet, or more than 1 joint, are referred to a rheumatology service within 3 working days of presentation.

Quality standard measure: Proportion of people with suspected persistent synovitis affecting the small joints of the hands or feet, or more than 1 joint, who are referred to a rheumatology service within 3 working days of presentation.
What was measured: Proportion of people with early inflammatory arthritis referred to a referred to a rheumatology service within three days of presentation to primary care.
Data collection end: April 2015
17%
Data collection end: January 2016
20%
Number that met the criteria: 1020
Area covered: England and Wales
Source: The British Society for Rheumatology. National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.


Statement: 2

People with suspected persistent synovitis are assessed in a rheumatology service within 3 weeks of referral.

Quality standard measure: Proportion of people with suspected persistent synovitis who are assessed in a rheumatology service within 3 weeks of referral.
What was measured: Proportion of people with early inflammatory arthritis who were seen within 3 weeks of receipt of referral to rheumatology service
Data collection end: April 2015
38%
Data collection end: January 2016
37%
Number that met the criteria: 1844
Area covered: England and Wales
Source: The British Society for Rheumatology. National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.


Statement: 3

People with newly diagnosed rheumatoid arthritis are offered short-term glucocorticoids and a combination of disease-modifying anti-rheumatic drugs by a rheumatology service within 6 weeks of referral.

Quality standard measure: Proportion of people with newly diagnosed rheumatoid arthritis who receive short-term glucocorticoids and a combination of disease-modifying anti-rheumatic drugs from a rheumatology service within 6 weeks of referral.
What was measured: Proportion of people with rheumatoid arthritis commencing any disease-modifying anti-rheumatic drug therapy within 6 weeks of a receipt of their referral.
Data collection end: April 2015
53%
Data collection end: January 2016
68%
Number that met the criteria: 2170
Area covered: England and Wales
Source: The British Society for Rheumatology. National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.


Statement: 4

People with rheumatoid arthritis are offered educational and self-management activities within 1 month of diagnosis.

Quality standard measure: Proportion of people with rheumatoid arthritis who are offered educational and self-management activities within 1 month of diagnosis.
What was measured: Proportion of people with rheumatoid arthritis who were offered educational and self-management activities within 1 month of diagnosis when they returned for follow up.
Data collection end: April 2015
59%
Data collection end: January 2016
67%
Number that met the criteria: 1438
Area covered: England and Wales
Source: The British Society for Rheumatology. National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.


Statement: 5

People who have active rheumatoid arthritis are offered monthly treatment escalation until the disease is controlled to an agreed low disease activity target.

Quality standard measure: Proportion of people with active rheumatoid arthritis who receive monthly treatment escalation.
What was measured: Proportion of people with rheumatoid arthritis who had a treatment target set at their initial visit.
Data collection end: January 2016
89%
Number that met the criteria: 2831
Area covered: England and Wales
Source: The British Society for Rheumatology. National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.


Statement: 6

People with rheumatoid arthritis and disease flares or possible drug-related side effects receive advice within 1 working day of contacting the rheumatology service.

Quality standard measure: Evidence of local arrangements for people with rheumatoid arthritis and disease flares or possible drug-related side effects receive advice within 1 working day of contacting the rheumatology service.
What was measured: Proportion of Trusts that reported access to a telephone advice service for people with inflammatory arthritis who had a flare of arthritis.
Data collection end: April 2015
96%
Data collection end: January 2016
92%
Number that met the criteria: 4597
Area covered: England and Wales
Source: The British Society for Rheumatology. National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.


Statement: 7

People with rheumatoid arthritis have a comprehensive annual review that is coordinated by the rheumatology service.

Quality standard measure: Evidence of local arrangements for people with rheumatoid arthritis to have a comprehensive annual review that is coordinated by the rheumatology service.
What was measured: Proportion of Trusts that reported that they had a formal or informal annual review process in place for people with rheumatoid arthritis.
Data collection end: April 2015
100%
Data collection end: January 2016
82%
Area covered: England and Wales
Source: The British Society for Rheumatology. National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.

Quality standard measure: Proportion of people with rheumatoid arthritis diagnosed more than 1 year ago whose last comprehensive review was within 12 months of diagnosis or the previous review.
What was measured: Proportion of patients with rheumatoid arthritis, on the register, who have had a face-to-face review in the preceding 12 months.
Data collection end: July 2015
84.3%
Area covered: England
Source: Health and Social Care Information Centre. Quality Outcomes Framework.



 Return to QS33 Overview